DK2001293T3 - Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse - Google Patents

Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse Download PDF

Info

Publication number
DK2001293T3
DK2001293T3 DK07797196.8T DK07797196T DK2001293T3 DK 2001293 T3 DK2001293 T3 DK 2001293T3 DK 07797196 T DK07797196 T DK 07797196T DK 2001293 T3 DK2001293 T3 DK 2001293T3
Authority
DK
Denmark
Prior art keywords
approx
composition
chain triglycerides
mct
subjects
Prior art date
Application number
DK07797196.8T
Other languages
English (en)
Inventor
Samuel T Henderson
Original Assignee
Accera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accera Inc filed Critical Accera Inc
Application granted granted Critical
Publication of DK2001293T3 publication Critical patent/DK2001293T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Claims (33)

1. Anvendelse af mellemkædetriglycerider (MCT'er) til fremstilling af en sammensætning til behandling af aldersrelateret hukommelsessvækkelse (AAMI) hos et menneske, hvor mellemkædetriglyceriderne har formlen: ' 1 I HlC-Rj hvor R1, R2 og R3 esterificeret til glycerol-backbone hver uafhængigt er fedtsyrer med 5-12 carbonkæder.
2. Anvendelse ifølge krav 1, hvor mere end 95 % af R1-, R2- og R3-carbon-kæderne har en længde på 8 carboner.
3. Anvendelse ifølge krav 2, hvor de resterende R1-, R2- og R3-carbonkæder er 6-carbon- eller 10-carbonkæder.
4. Anvendelse ifølge krav 1, hvor ca. 50 % af R1-, R2- og R3-carbonkæderne har en længde på 8 carboner, og ca. 50 % af R1-, R2- og R3-carbonkæderne har en længde på ca. 10 carboner.
5. Anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor sammensætningen yderligere omfatter glucose.
6. Anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor sammensætningen er til indgivelse af mellemkædetriglycerider i en mængde, der er virksom til at inducere hyperketonæmi.
7. Anvendelse ifølge krav 6, hvor hyperketonæmi fører til, at ketonstoffer anvendes til energi i hjernen.
8. Anvendelse af et hvilket som helst af kravene 1 til 7, hvor sammensætningen øger den cirkulerende koncentration af mindst et ketonstof hos pattedyret.
9. Anvendelse ifølge krav 8, hvor mængden af β-hydroxybutyrat øges i pattedyrets blod.
10. Anvendelse ifølge krav 9, hvor mængden af β-hydroxybutyrat øges til mellem ca. 0,1 millimolar til ca. 10 millimolar ca. to timer efter indgivelse.
11. Anvendelse ifølge krav 9, hvor mængden af β-hydroxybutyrat øges til mellem ca. 0,15 millimolar til ca. 0,3 millimolar ca. to timer efter indgivelse.
12. Anvendelse ifølge krav 9, hvor urinudskillelsesniveauet af β-hydroxybuty-rat øges til ca. 5 til ca. 160 mg/dl.
13. Anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor sammensætningen er til indgivelse i en dosis på ca. 0,05 g/kg/dag til ca. 10 g/kg/dag af mellemkædetriglycerider.
14. Anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor sammensætningen er til indgivelse i en dosis på ca. 0,1 g/kg/dag til ca. 2 g/kg/dag af mellemkædetriglycerider.
15. Anvendelse ifølge et hvilket som helst af kravene 1 til 14, hvor sammensætningen er en drikkeklar drik, en pulverdrikformulering, et ernærings- eller kosttilskud udvalgt fra gruppen bestående af gelatinekapsel eller tablet, suspension, parenteral opløsning eller et fødevareprodukt formuleret til menneskeføde.
16. Anvendelse ifølge et hvilket som helst af kravene 1 til 15, hvor sammensætningen er til indgivelse regelmæssigt, omfattende mindst en gang dagligt.
17. Anvendelse ifølge krav 16, hvor sammensætningen er til indgivelse som en del af et dagligt behandlingsregime i mindst ca. en uge.
18. Anvendelse ifølge krav 16, hvor sammensætningen er til indgivelse som en del af et dagligt behandlingsregime i mindst ca. tre måneder.
19. Anvendelse ifølge et hvilket som helst af kravene 1 til 18, hvor sammensætningen er til anvendelse i behandlingen af et pattedyr, som er ApoE4(-).
20. Anvendelse ifølge et hvilket som helst af kravene 1 til 19, hvor effektiviteten til behandling af AAMI bestemmes ved hjælp af resultater af mindst en neuropsykologisk test.
21. Anvendelse ifølge krav 20, hvor den neuropsykologiske test er udvalgt fra gruppen bestående af CGIC (Clinical Global Impression of Change), RAVLT (Rey Auditory Verbal Learning Test), FLN (First-Last Names Association Test), TDT (Telephone Dialing Test), MAC-S (Memory Assessment Clinics Self-Rating Scale), SDC (Symbol Digit Coding), DRT (SDC Delayed Recall Task), DAT (Divided Attention Test), VSC (Visual Sequence Comparison), DAT Dual (DAT Dual Task) og geriatrisk depressionsskala (GDS).
22. Sammensætning omfattende mellemkædetriglycerider (MCT) til anvendelse til behandling af aldersrelateret hukommelsessvækkelse (AAMI) hos et menneske, hvor mellemkædetriglyceriderne har formlen: " 1' I KgC—>3 hvor R1, R2 og R3 esterificeret til glycerol-backbone hvert uafhængigt er fedtsyrer med 5-12 carbonkæder.
23. Sammensætning omfattende mellemkædetriglycerider til anvendelse til behandling af AAMI ifølge krav 22, hvor mere end 95 % af R1-, R2- og R3-carbonkæderne har en længde på 8 carboner, og eventuelt hvor de resterende R1-, R2- og R3-carbonkæder er 6-carbon- eller 10-carbonkæder.
24. Sammensætning omfattende mellemkædetriglycerider til anvendelse til behandling af AAMI ifølge krav 22, hvor ca. 50 % af R1-, R2- og R3-carbon-kæderne har en længde på 8 carboner, og ca. 50 % af R1 -, R2- og R3-carbon-kæderne har en længde på ca. 10 carboner.
25. Sammensætning omfattende mellemkædetriglycerider til anvendelse til behandling af AAMI ifølge et hvilket som helst af kravene 22 til 24, hvor MCT er i en sammensætning omfattende MCT og glucose.
26. Sammensætning omfattende mellemkædetriglycerider til anvendelse til behandling af AAMI ifølge et hvilket som helst af kravene 22 til 25, hvor mængden af β-hydroxybutyrat øges i pattedyrets blod til mellem ca. 0,1 millimolar til ca. 10 millimolar ca. to timer efter indgivelse, eller hvor MCT'en øger urinudskillelsesniveauet af β-hydroxybutyrat øges til ca. 5 til ca. 160 mg/dl.
27. Sammensætning omfattende mellemkædetriglycerider til anvendelse til behandling af AAMI ifølge et hvilket som helst af kravene 22 til 26, hvor dosen af MCT er ca. 0,05 g/kg/dag til ca. 10 g/kg/dag.
28. Ernæringsdrik til oral indtagelse til anvendelse til behandling af aldersrelateret hukommelsessvækkelse (AAMI), hvilken ernæringsdrik omfatter: en enhedsdosis af mellemkædetriglycerider (MCT), der er tilstrækkelig til at a) øge blodniveauer af D^-hydroxybutyrat til ca. 0,1 til ca. 5 mM eller b) øge urinudskillelsesniveauer af □-β-hydroxybutyrat til ca. 5 mg/dl til ca. 160 mg/dl; L-car-nitin, en flerhed af vitaminer; smagsstof og en kulhydratkilde, og hvor mellem-kædetriglyceriderne har formlen: -j i hvor R1, R2 og R3 esterificeret til glycerol-backbone hvert uafhængigt er fedtsyrer med carbonkæder på 5-12 carboner.
29. Ernæringsdrik til anvendelse til behandling af AAMI ifølge krav 28, hvor mere end 95 % af R1-, R2- og R3-carbonkæderne har en længde på 8 carboner.
30. Ernæringsdrik til anvendelse til behandling af AAMI ifølge krav 29, hvor de resterende R1, R2 og R3 er 6-carbon- eller 10-carbonkæder.
31. Ernæringsdrik til anvendelse til behandling af AAMI ifølge krav 28, hvor ca. 50 % af R1-, R2- og R3-carbonkæderne har en længde på 8 carboner, og ca. 50 % af R1-, R2- og R3-carbonkæderne har en længde på ca. 10 carboner.
32. Ernæringsdrik til anvendelse til behandling af AAMI ifølge krav 28, som er en fødevaresammensætning, yderligere omfattende, på tørvægtbasis, ca. 5-50 % protein, ca. 5-40 % fedt, ca. 5-40 % kulhydrat og med et fugtindhold på ca. 5-20 %.
33. Ernæringsdrik til anvendelse til behandling af AAMI ifølge krav 28, omfattende mindst ca. 1 % til ca. 50 % MCT på tørvægtbasis.
DK07797196.8T 2006-04-03 2007-04-03 Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse DK2001293T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74414006P 2006-04-03 2006-04-03
PCT/US2007/065873 WO2007115282A2 (en) 2006-04-03 2007-04-03 Use of ketogenic compounds for treatment of age-associated memory impairment

Publications (1)

Publication Number Publication Date
DK2001293T3 true DK2001293T3 (da) 2018-11-19

Family

ID=38564302

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12160599.2T DK2500017T3 (da) 2006-04-03 2007-04-03 Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
DK07797196.8T DK2001293T3 (da) 2006-04-03 2007-04-03 Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12160599.2T DK2500017T3 (da) 2006-04-03 2007-04-03 Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse

Country Status (11)

Country Link
US (3) US8124589B2 (da)
EP (2) EP2001293B9 (da)
JP (4) JP2009532496A (da)
KR (2) KR20090003148A (da)
DK (2) DK2500017T3 (da)
ES (2) ES2697504T3 (da)
HU (2) HUE035852T2 (da)
LT (2) LT2500017T (da)
PT (2) PT2001293T (da)
SI (1) SI2001293T1 (da)
WO (1) WO2007115282A2 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
ES2323940T3 (es) 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ES2670413T3 (es) 2003-06-03 2018-05-30 The United States Government As Represented By The Department Of Health And Human Services Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US20070135376A1 (en) * 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
AU2006326040B2 (en) * 2005-12-15 2012-02-09 Société des Produits Nestlé S.A. Compositions and methods for preserving brain function
EP2001293B9 (en) 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
CA2685380A1 (en) * 2007-05-14 2008-11-20 Neuera Pharmaceuticals, Inc. Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism
PT2650378E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
EP3058942B2 (en) * 2008-01-04 2023-03-22 Société des Produits Nestlé S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
AU2009204370B2 (en) 2008-01-04 2014-12-04 Gvmt Of The Usa, As Represented By The Secretary, Department Of Health & Human Services Ketone bodies and ketone body esters as blood lipid lowering agents
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
CN105640931A (zh) 2008-07-03 2016-06-08 艾克塞拉公司 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物
CA2730940A1 (en) * 2008-07-18 2010-01-21 Dart Neuroscience Llc Methods and systems for evaluating memory agents
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
JP5059947B2 (ja) 2008-11-06 2012-10-31 日清オイリオグループ株式会社 濃厚流動食
ES2640777T3 (es) 2009-12-30 2017-11-06 Baylor Research Institute Terapia anaplerótica para la enfermedad de Alzheimer
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
AU2011229969A1 (en) * 2010-03-24 2012-09-20 Nestec S.A. Methods for enhancing the palatability of comestible compositions
ES2752030T3 (es) 2012-11-05 2020-04-02 Us Health Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
CN104955450A (zh) 2012-12-13 2015-09-30 达拉斯贝勒研究院 用于治疗葡萄糖转运体1缺乏症的三庚酸甘油酯
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
CN105050594B (zh) * 2013-03-19 2019-11-12 南佛罗里达大学 用于产生升高和持久的酮症的组合物和方法
EP3068492B1 (en) 2013-11-14 2020-01-08 The University of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
US20170202239A1 (en) * 2014-07-17 2017-07-20 The Nisshin Oillio Group, Ltd. Baked confectionery that substantially includes no flour
WO2016013617A1 (ja) * 2014-07-23 2016-01-28 一般財団法人糧食研究会 脳機能改善剤、及び認知機能障害の予防または治療剤
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
AU2015358958B2 (en) 2014-12-08 2020-10-01 Société des Produits Nestlé S.A. Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
JP6446265B2 (ja) * 2014-12-26 2018-12-26 花王株式会社 固形状組成物
EP3419959A4 (en) * 2016-02-23 2019-10-23 Carnot, LLC COMBINATION THERAPY
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
JP6923940B2 (ja) * 2016-04-15 2021-08-25 慶裕 広川 認知機能改善剤
JP6935994B2 (ja) 2016-08-19 2021-09-15 株式会社明治 ケトン体生成促進用組成物
EP3528802A4 (en) * 2016-10-24 2020-05-13 University Of South Florida DELAY IN LATENCY LEADING TO A CRISIS BY COMBINATIONS OF KETONIC SUPPLEMENTS
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
JP6895144B2 (ja) * 2017-04-05 2021-06-30 北海道公立大学法人 札幌医科大学 診断支援システム、診断支援システムの作動方法、及びプログラム
US10510328B2 (en) * 2017-08-31 2019-12-17 Spotify Ab Lyrics analyzer
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
CA3099624A1 (en) * 2018-06-21 2019-12-26 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
WO2020167690A1 (en) * 2019-02-11 2020-08-20 Access Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
AU2020221916A1 (en) * 2019-02-11 2021-09-02 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
KR20210135551A (ko) * 2019-03-04 2021-11-15 세레신 인코포레이티드 개선된 생체이용률을 갖는 중쇄 트리글리세라이드 제제 및 이와 관련된 방법
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
JP7458620B2 (ja) 2019-06-21 2024-04-01 株式会社大塚製薬工場 栄養組成物
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
JP7010509B2 (ja) * 2020-01-15 2022-01-26 一般社団法人 Unical 新規配合スポーツ飲料およびその調製のための顆粒剤
EP4114203A1 (en) 2020-03-05 2023-01-11 VitaNav, Inc. COMPOSITION OF (D)-ß-HYDROXYBUTYRIC ACID, (D)-ß-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT
US20230277484A1 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health
WO2023183545A1 (en) * 2022-03-24 2023-09-28 Cerecin Inc. Systems, methods, and devices for predicting pharmacokinetic influences on ketogenesis following administration of tricaprilin
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2766145A (en) 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US2766146A (en) 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US3053677A (en) 1959-11-12 1962-09-11 Eastman Kodak Co Petroleum wax for paper coatings
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
FR2490631A1 (fr) 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4551523A (en) 1983-04-14 1985-11-05 Eastman Kodak Company Preparation of saccharide acetoacetates
US4847296A (en) 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
SE8803141L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE3843238C1 (da) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
IT1240775B (it) 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
CA2079890C (en) 1990-04-26 1996-12-03 James Carey Letton Shortening compositions containing polyol fatty acid polyesters
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
GB9113484D0 (en) 1991-06-21 1991-08-07 Unilever Plc Cosmetic composition
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE625212T1 (de) 1992-10-13 2000-11-02 Univ Durham Verfahren zum entdecken von krankheit von alzheimer.
JP3486778B2 (ja) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
US5420335A (en) 1993-09-30 1995-05-30 Birkhahn; Ronald H. Parenteral nutrients based on watersoluble glycerol bisacetoacetates
WO1995009145A1 (en) * 1993-09-30 1995-04-06 Eastman Chemical Company NUTRITIVE GLYCEROL ESTERS OF β-ACYLOXY BUTYRATES
US5438042B1 (en) 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5691325A (en) * 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
GB9408465D0 (en) 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US7049078B2 (en) 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
US5607967A (en) 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
EP1719510A1 (en) 1994-11-08 2006-11-08 Avicenda Group, Inc. Use of creatine or creatine analogs for the tratment of diseases of the nervous system
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6022683A (en) 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
DE19609476A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
IT1284650B1 (it) 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
KR980008239A (ko) 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
EP1006794B1 (en) 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
ES2530753T3 (es) 1997-03-17 2015-03-05 Btg Int Ltd Composiciones terapéuticas que comprenden cuerpos cetónicos y precursores de los mismos
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
US20040058873A1 (en) 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
JP2002510604A (ja) 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
EP1098655B1 (en) * 1998-07-22 2004-11-24 Metabolix, Inc. Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
AU6039199A (en) 1998-09-14 2000-04-03 Pan Pacific Pharmaceuticals, Inc. Useful properties of a bee venom protein and gene encoding same
WO2000015216A1 (en) 1998-09-15 2000-03-23 Btg International Limited Therapeutic compositions (ii)
GB9908202D0 (en) 1999-04-12 1999-06-02 Unilever Plc Cosmetic compositions
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ES2323940T3 (es) * 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US20070179197A1 (en) 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
DE20012857U1 (de) 2000-07-27 2000-11-09 Sportmedizin Team Vertriebs Gm Diätetisches Lebensmittel zum Fettabbau
US6667397B2 (en) 2000-08-25 2003-12-23 Eastman Chemical Company Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom
GB2368011A (en) 2000-10-17 2002-04-24 Unilever Plc Fatty acid esters of maltose and uses thereof
US20020103139A1 (en) 2000-12-01 2002-08-01 M. Weisspapir Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control
KR100479741B1 (ko) 2000-12-30 2005-03-30 주식회사 엘지생활건강 글루코오스 아실화 유도체 또는 수크로오스 아실화유도체를 함유하는 피부미백제
WO2002098398A1 (en) 2001-06-07 2002-12-12 Eisai Co., Ltd. Methods for preventing and treating diseases and conditions associated with cellular stress
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20030059824A1 (en) 2001-09-21 2003-03-27 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
US7320806B2 (en) 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
US6884454B2 (en) * 2002-10-21 2005-04-26 Julio Lionel Pimentel Appetite suppressing diet bar
JP3660997B2 (ja) * 2002-11-26 2005-06-15 独立行政法人情報通信研究機構 ３次元電界分布測定方法および３次元電界分布測定装置
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CA2517929A1 (en) 2003-03-06 2004-09-16 Accera Inc. Novel-chemical entities and methods for their use in treatment of metabolic disorders
ES2670413T3 (es) * 2003-06-03 2018-05-30 The United States Government As Represented By The Department Of Health And Human Services Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato
US20050013884A1 (en) 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
US7148192B2 (en) * 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
US20060252775A1 (en) 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
AU2006326040B2 (en) * 2005-12-15 2012-02-09 Société des Produits Nestlé S.A. Compositions and methods for preserving brain function
EP2001293B9 (en) 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose

Also Published As

Publication number Publication date
US8124589B2 (en) 2012-02-28
JP2018080175A (ja) 2018-05-24
US20140256808A1 (en) 2014-09-11
HUE040002T2 (hu) 2019-02-28
ES2645816T3 (es) 2017-12-07
US8748400B2 (en) 2014-06-10
EP2001293B9 (en) 2019-04-17
EP2001293B1 (en) 2018-08-29
EP2500017A1 (en) 2012-09-19
LT2001293T (lt) 2018-11-12
EP2001293A2 (en) 2008-12-17
KR20090003148A (ko) 2009-01-09
EP2500017B1 (en) 2017-09-06
JP2016121128A (ja) 2016-07-07
PT2500017T (pt) 2017-11-14
SI2001293T1 (sl) 2018-12-31
KR20150018897A (ko) 2015-02-24
JP2009532496A (ja) 2009-09-10
LT2500017T (lt) 2017-12-11
ES2697504T3 (es) 2019-01-24
KR101634083B1 (ko) 2016-06-28
PT2001293T (pt) 2018-11-28
US20080287372A1 (en) 2008-11-20
HUE035852T2 (en) 2018-05-28
EP2001293A4 (en) 2009-09-23
US20120122978A1 (en) 2012-05-17
WO2007115282A2 (en) 2007-10-11
WO2007115282A3 (en) 2007-12-21
DK2500017T3 (da) 2017-11-06
JP2013082716A (ja) 2013-05-09
JP5847693B2 (ja) 2016-01-27

Similar Documents

Publication Publication Date Title
DK2001293T3 (da) Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
US20070179197A1 (en) Compositions and methods for improving or preserving brain function
AU2016202685B2 (en) Compositions and methods for enhancing cognitive function
US10111849B2 (en) Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
CA2709660C (en) Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US20080009467A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
BRPI0619905A2 (pt) composições e métodos para conservar função cerebral
CN103764136A (zh) 用于治疗、减轻或预防动物神经系统损害的方法和组合物
JP5674652B2 (ja) 神経障害の処置のためのアセトアセテートのモノグリセリドおよび誘導体
WO2009005519A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US20230181512A1 (en) Methods for the treatment of infantile spasms using medium chain triglycerides
AU2022329943A1 (en) Methods for the treatment of migraine and related headache symptoms using tricaprylin